Literature DB >> 9008292

Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques.

M Ohlin1, M Silvestri, V A Sundqvist, C A Borrebaeck.   

Abstract

An electrochemiluminescence technique was used to develop versatile and sensitive assay strategies for determination of seroreactivities against biologically important cytomegalovirus neutralization epitopes expressed on glycoprotein B. Indirect binding assays showed wide linear assay ranges and revealed that serum samples diluted in parallel with a monoclonal antibody-based standard, simplifying quantitative analytical assessments.

Mesh：

Substances：

Year:  1997        PMID： 9008292      PMCID： PMC170486          DOI： 10.1128/cdli.4.1.107-111.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


  23 in total

1.  The gene encoding the biotin carboxylase subunit of Escherichia coli acetyl-CoA carboxylase.

Authors:  S J Li; J E Cronan
Journal:  J Biol Chem       Date:  1992-01-15       Impact factor: 5.157

2.  Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins.

Authors:  M Sällberg; U Rudén; L O Magnius; E Norrby; B Wahren
Journal:  Immunol Lett       Date:  1991-09       Impact factor: 3.685

3.  An interchangeable ELISA for cytomegalovirus antigen and antibody.

Authors:  V A Sundqvist; B Wahren
Journal:  J Virol Methods       Date:  1981-04       Impact factor: 2.014

4.  Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus.

Authors:  M Ohlin; V A Sundqvist; G Gilljam; U Rudén; F O Gombert; B Wahren; C A Borrebaeck
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

5.  Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.

Authors:  W J Britt; L Vugler; E J Butfiloski; E B Stephens
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

6.  Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus.

Authors:  N Kniess; M Mach; J Fay; W J Britt
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

7.  The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope.

Authors:  H Meyer; Y Masuho; M Mach
Journal:  J Gen Virol       Date:  1990-10       Impact factor: 3.891

8.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

Authors:  S R Riddell; K S Watanabe; J M Goodrich; C R Li; M E Agha; P D Greenberg
Journal:  Science       Date:  1992-07-10       Impact factor: 47.728

Review 9.  Current prospects for immunization against cytomegaloviral disease.

Authors:  S P Adler
Journal:  Infect Agents Dis       Date:  1996-01

10.  The preclinical safety evaluation of human monoclonal antibody against cytomegalovirus.

Authors:  K Matsuzawa; T Koyama; S Sugawara; S Ikegawa; S Asano; S Sasaki; T Tomiyama; Y Kasahara; Y Okamiya; K Inoue
Journal:  Fundam Appl Toxicol       Date:  1992-07
View more
  1 in total

1.  Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.

Authors:  Adam C Finnefrock; Daniel C Freed; Aimin Tang; Fengsheng Li; Xi He; Chengwei Wu; Debbie Nahas; Dai Wang; Tong-Ming Fu
Journal:  Hum Vaccin Immunother       Date:  2016-03-17       Impact factor: 3.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.